Senesco Closes Enrollment in Its Phase 1b/2a SNS01-T Study Bridgewater, N.J. (

Senesco Closes Enrollment in Its Phase

Bridgewater, N.J. (August 29, 2014) - Senesco

Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) today announced the closing of enrollment

in its ongoing Phase 1b/2a open-label, multiple-dose, dose-escalation clinical trial of SNS01-T, a first-in-class modulator of

eukaryotic translation initiation factor 5A (eIF5A), in patients with relapsed or refractory multiple myeloma, plasma cell leukemia

The safety portion of the study has established a maximum tolerated

dose following the reporting of a second dose limiting toxicity (DLT) in the fourth and highest dosing cohort (0.375 mg/kg). The

first DLT observed was a Grade 4 infusion reaction that occurred in a patient who had not received the designated premedications.

The second DLT, an uncomplicated Grade 4 neutropenia, occurred after eight doses in a lymphoma patient. A total of eight patients

were enrolled into cohort 4. With the completion of the high dose cohort, the trial will stop recruitment. All patients currently

enrolled may continue treatment at the recommended cohort 3 dose level of 0.2 mg/kg and will be monitored through completion of

their study treatment. The Company will submit the clinical, pharmacokinetic and pharmacodynamic data from the study for presentation

at an upcoming scientific meeting.

"The eIF5A gene, with its ability to regulate programmed

cell death and cell survival, is a promising target with broad potential application in multiple disease areas," said Ronald

A. Martell, Chief Executive Officer of Senesco. "The primary goal of this study was to assess safety and tolerability of

our lead eIF5a product candidate, SNS01-T, at various dose levels. Having now reached a maximum tolerated dose, we will look to

the final study results to inform our future development."

SNS01-T is a novel approach to cancer therapy that is designed

to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and mantle cell and diffuse large B-cell lymphomas.

Senesco is the sponsor of a Phase 1b/2a study which enrolled patients at Mayo Clinic in Rochester, MN, the University of Arkansas

for Medical Sciences in Little Rock, the Mary Babb Randolph Cancer Center in Morgantown, WV, the John Theurer Cancer Center at

Hackensack University Medical Center in Hackensack, NJ, the Seattle Cancer Care Alliance in Seattle, WA, and, the Pretoria East

Hospital, in Pretoria and the Groote Schuur Hospital in Cape Town, South Africa.

Senesco Technologies is a clinical-stage biotech company specializing

in cancer therapeutics and immunological diseases driven by a unique combination of gene regulation, antibody therapeutics and

nanocage delivery systems. Its proprietary gene regulation technology has demonstrated the ability to eliminate cancer cells and

protect healthy cells from premature death. The antibody approach is a novel discovery paradigm with the proven capability to identify

functional therapeutic monoclonal antibodies against challenging cell surface targets that previously have been highly resistant

to therapeutic antibody discovery. The Company is currently in a Phase 1b/2a trial with a product candidate that is designed to

treat B-cell cancers, which include multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's B-cell lymphomas. The

Company has several antibodies in its preclinical pipeline. The first to move forward is a potentially first/best in class candidate

antibody that targets an ion channel important in autoimmunity and inflammation. For more information, please visit Senesco.com

or connect with us on Facebook, Twitter, LinkedIn and Google+.

Forward-Looking Statements

Certain statements included in this press release are forward-looking

statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from

such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company's

ability to integrate the Fabrus science and operations; the Company's ability to continue as a going concern; the Company's

ability to recruit patients for its clinical trial; the ability of the Company to consummate additional financings; the development

of the Company's gene and antibody technology; the approval of the Company's patent applications; the current uncertainty

in the patent landscape surrounding small inhibitory RNA and the Company's ability to successfully defend its intellectual

property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the

Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance

by the market of the Company's products; the timing and success of the Company's preliminary studies, preclinical research

and clinical trials; competition and the timing of projects and trends in future operating performance; and the quotation of the

Company's common stock on an over-the-counter securities market, as well as other factors expressed from time to time in

the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press

release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained

herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking

statements to reflect subsequent events or circumstances.